Kamal K Sharma Designation: Managing Director, Lupin The Challenge: To enter the Japanese market, the world's second largest pharmaceutical market How He Did It: By entering the market with a partner and using them to understand the nuances. Lupin eventually bought the partner out, but made sure no changes were made to its management or operations In Japan, you just can't walk in and do business. It is a market...
04:46 PM, May 11, 2012
Mumbai: Share prices of Ranbaxy tumbled nearly 7 per cent in the morning trade on Friday after a consent decree was filed in a United States court that requires the drug firm to make fundamental changes at its plants in the US and India. The US Justice Department filed a "ground-breaking" consent decree in court on Thursday, mandating Indian drug-maker Ranbaxy to adhere to US manufacturing standards and ensure integrity...
12:01 PM, Jan 27, 2012
Washington: Indian pharma major Ranbaxy faces the possibility of a permanent injunction, which requires it to make fundamental changes to its plants both in the US and India and would prevent it from manufacturing drugs at certain facilities in the US. This follows the US Justice Department's unprecedented action in filing a ground-breaking consent decree in a court in Maryland at the request of the Food and Drug Administration. "This...
06:00 PM, Jan 26, 2012
Cipla, Ranbaxy, Hetero, Roche and Natco Pharma are in the race. ...
12:37 AM, Aug 13, 2009
Atul Sobti says that Ranbaxy will remain a listed company. ...
01:47 PM, May 25, 2009
Indian pharma giant has customers in 125 countries and alliances in 49 countries. ...
06:08 PM, May 24, 2009
Company says it will respond to American regulator's letter. ...
11:32 AM, Feb 26, 2009
Ranbaxy CEO will also assume the role of an Executive Chairman. ...
02:55 AM, Dec 20, 2008
The motion claimed that Ranbaxy had failed to comply FDA standards. ...
05:49 PM, Oct 08, 2008
Rudy Guiliani will help Ranbaxy resolve a US Food and Drug ban. ...
04:21 PM, Sep 18, 2008
Ranbaxy-Daiichi Sankyo is still good despite the co's trouble with US laws. ...
03:47 AM, Sep 18, 2008
US FDA banned more than 30 generic drugs produced by Ranbaxy. ...
10:44 AM, Sep 17, 2008
Sensex fell 45 points to 13473 and the Nifty lost 11 points at 4,064. ...
10:44 AM, Sep 17, 2008
The Indian drug giant, Ranbaxy is a major maker of an AIDS generic drug. ...
01:45 AM, Sep 17, 2008
Daiichi Sankyo to pump in Rs 10,000 crores to acquire stake in Ranbaxy. ...
05:49 PM, Aug 05, 2008
displayed with permission. Use of the CNN name and/or logo on or as part of CNN-IBN does not derogate from the intellectual property rights of Cable News Network in respect of them.
Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.
Disclaimer: TV18 Broadcast Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.
